Bachem Holding AG stock (CH0012530207): peptide specialist in focus after recent earnings and expansion plans

Bachem Holding AG remains in focus after reporting 2024 results and outlining capacity expansion and pipeline plans, keeping the peptide and oligonucleotide specialist on the radar of healthcare investors.

Bachem Holding AG is drawing renewed attention from healthcare and biotech investors after publishing its full-year 2024 results and updating the market on its capacity expansion and strategic priorities in peptide and oligonucleotide manufacturing, according to a company release dated 03/18/2025 and coverage by Reuters on 03/18/2025 (Bachem financial reporting as of 03/18/2025; Reuters as of 03/18/2025).

As of: 05/18/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Bachem
• Sector/industry: Life sciences, contract development and manufacturing (CDMO)
• Headquarters/country: Bubendorf, Switzerland
• Core markets: Global pharmaceutical and biotechnology customers, including Europe and North America
• Key revenue drivers: Custom and generic peptide active ingredients, oligonucleotides, research chemicals and related services
• Home exchange/listing venue: SIX Swiss Exchange (ticker: BANB)
• Trading currency: Swiss franc (CHF)

Bachem Holding AG: core business model

Bachem Holding AG is a Swiss-based contract development and manufacturing organization focused on peptides and oligonucleotides, two classes of molecules widely used in modern pharmaceuticals. The company manufactures active pharmaceutical ingredients and intermediates for branded and generic drugs, as well as research-grade products, according to its corporate profile updated in 2025 (Bachem company profile as of 02/2025).

The business is structured around custom manufacturing for large pharmaceutical and biotech clients, standard generic APIs and catalog products for research and diagnostics. This mix exposes Bachem both to long-term supply contracts for commercial drugs and to more cyclical research demand. The company emphasizes high-quality standards and regulatory compliance in key markets such as the United States and Europe.

Bachem operates production sites in Switzerland, Europe and the United States, allowing it to serve global customers and meet local regulatory and logistics requirements. The presence in the US is strategically important because many peptide and oligonucleotide drug developers are headquartered there, and the US remains the largest single market for prescription medicines by revenue, based on industry data published by IQVIA in 2024 (IQVIA as of 04/2024).

Main revenue and product drivers for Bachem Holding AG

Bachem’s revenue base is driven primarily by custom manufacturing contracts for peptide and oligonucleotide APIs that are used in clinical development programs and commercial drugs. The company reported that demand for complex peptides and oligonucleotides remained a key growth driver in its full-year 2024 report published on 03/18/2025, highlighting a robust project pipeline across multiple therapeutic areas (Bachem financial reporting as of 03/18/2025).

Beyond custom projects, sales of generic peptide APIs are another important revenue stream. These products are typically supplied to generic drug manufacturers and can benefit from volume growth once original branded peptides lose exclusivity. However, pricing in generics can be competitive, which may weigh on margins if input costs or capacity utilization are not managed carefully.

Bachem also generates revenue from research-grade peptides and catalog products that are sold to universities, biotech companies and diagnostic firms. While these products usually carry higher margins, the volumes and order patterns can be more volatile than those of long-term supply contracts. Overall, the combination of custom manufacturing, generics and research products provides a diversified source of revenue but also exposes the company to different demand cycles.

In its 2024 reporting, management underscored ongoing investments in production capacity and technology to support future revenue growth, particularly in large-scale peptide and oligonucleotide manufacturing. Such investments can temporarily weigh on profitability due to higher depreciation and operating expenses, but they are intended to position Bachem for rising demand from late-stage clinical and commercial projects in the coming years, according to the same 03/18/2025 disclosure (Bachem financial reporting as of 03/18/2025).

Industry trends and competitive position

The peptide and oligonucleotide CDMO market has been expanding as drug developers increasingly outsource complex manufacturing tasks. Industry research cited by Bachem in its 2024 reporting suggests that the number of peptide-based drug candidates in clinical development continues to grow, reflecting their use in metabolic diseases, oncology and rare disorders (Bachem publications as of 2024). Oligonucleotides, including antisense and siRNA therapies, are also gaining traction across multiple indications.

Within this landscape, Bachem competes with other specialized peptide and oligonucleotide manufacturers as well as broader CDMOs that offer multi-modal capabilities. Its long history in peptide chemistry, established regulatory track record and global footprint are frequently cited as competitive advantages. At the same time, the company faces pricing pressure and the need for continuous investment to keep capacity and technology aligned with customer requirements and regulatory expectations, according to commentary in its 2024 annual report released on 03/18/2025 (Bachem annual report as of 03/18/2025).

For US-focused investors, Bachem’s positioning as a supplier to North American biotech and pharmaceutical companies is a key consideration. Many of its customers are listed on US exchanges and depend on reliable supply chains for complex APIs. This creates an indirect link between the health of the US biotech funding environment and Bachem’s project pipeline, even though the stock itself trades in Swiss francs on the SIX Swiss Exchange.

Why Bachem Holding AG matters for US investors

Although Bachem is headquartered and listed in Switzerland, its relevance to US investors stems from its integration into the global biotech and pharmaceutical supply chain. A substantial portion of innovation in peptides and oligonucleotides originates from US-based companies, and Bachem positions itself as a partner for these firms throughout clinical development and commercialization, according to its investor presentations from 2024 and 2025 (Bachem investor presentations as of 2025).

For US portfolios with exposure to healthcare, life sciences tools or CDMOs, Bachem can represent a way to participate in the growth of complex peptide and oligonucleotide therapies outside of the domestic market. However, investors must also consider currency risk, since the stock trades in Swiss francs, and they should be aware of the differences in disclosure practices and market structure between SIX Swiss Exchange and major US exchanges.

Regulatory developments by the US Food and Drug Administration (FDA) can influence Bachem’s business indirectly. Approvals of peptide and oligonucleotide drugs that rely on outsourced manufacturing may support demand for CDMO services. Conversely, delays, safety concerns or shifts in reimbursement policies could impact the pace at which new products reach the market, potentially affecting volumes at suppliers such as Bachem, as discussed in broader sector analyses by S&P Global published in 2024 (S&P Global healthcare outlook as of 11/2024).

Conclusion

Bachem Holding AG occupies a specialized niche in the global CDMO landscape, focusing on peptides and oligonucleotides that are central to many current and emerging therapies. Recent financial reporting and expansion plans underline both the growth opportunities and the investment needs associated with this position. For US-oriented investors, the stock provides exposure to a technical area of drug manufacturing that is closely linked to innovation in the US biotech sector, while also introducing considerations such as Swiss franc currency risk, differing market regulations and capacity expansion execution. As with any individual stock, the balance between growth prospects, operational risks and valuation will likely shape future investor interest and share price performance.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.